IVEVF (Inventiva) Valuation Rank


IVEVF Inventiva SA IVEVF
34 GF Score
Price $3.59
GF Value $0.29
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Inventiva Valuation Rank Related Terms

IVEVF
34GF Score
Inventiva SA IVEVF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inventiva (IVEVF) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.59 is trading 1137.9% above its estimated GF Value™ of $0.29. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVEVF:

  • Valuation Rank:
  • GF Value™: $0.29 vs. price of $3.59 (1137.9% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
34GF Score

Get the complete analysis for IVEVF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$0.29
GF Value